NF1 Mutation clinical trials at UCSF
1 research study open to eligible people
An NF1 mutation is a genetic change that may lead to tumors. UCSF is studying a new treatment, DCC-3084, for cancers driven by the MAPK pathway. This research is in its first and second phases and is being conducted at various sites.
Showing trials for
DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
open to eligible people ages 18 years and up
This is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional…
San Francisco, California and other locations
Our lead scientists for NF1 Mutation research studies include Rahul Aggarwal.
Last updated: